- 2010.3.11
- Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia (PDF43kb)
- 2010.2.19
- Change of Executive Officers and Merger of Two Subsidiaries in North America (PDF54kb)
- 2010.2.15
- Second Mid-term Business Plan(PDF54kb)
- 2010.2.3
- Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2010 (Unaudited)(PDF790kb)
- 2010.2.3
- Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010 (PDF1120kb)
- 2010.2.3
- Revision of Financial Forecasts for the Year Ending March 31, 2010 (PDF58kb)
- 2010.1.28
- FDA extends PDUFA action date for STEDESA new drug application(PDF47kb)
- 2010.1.25
- DSP Group Contributes to Haiti Earthquake Relief Efforts(PDF43kb)
- 2010.1.21
- JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign a Letter of Intent for the assignment and acceptance of the growth hormone business(PDF63kb)
- 2010.1.21
- Company Split (Incorporation-type Company Split）of the Company’s Animal Health Products business (PDF89kb)
- 2010.1.21
- Company Split (Absorption-type Company Split） of the Company’s Food & Speciality Products business(PDF92kb)
- 2010.1.20
- Oral hypoglycemic drug METGLUCO obtained a manufacturing and marketing approval (PDF41kb)
- 2010.1.20
- Acquisition of an additional indication of MEROPEN, a carbapenem antibiotic preparation (PDF69kb)
- 2010.1.5
- Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia (PDF71kb)
